Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9804 Medical Center Drive ROCKVILLE MD 20850 |
Tel: | N/A |
Website: | https://regenxbio.com |
IR: | See website |
Key People | ||
Kenneth T. Mills President, Chief Executive Officer, Director | Vittal K. Vasista Chief Financial Officer, Executive Vice President | Curran M. Simpson Chief Operating Officer, Executive Vice President |
Olivier Danos Executive Vice President, Chief Scientific Officer | Patrick J. Christmas Executive Vice President, Chief Legal Officer | Steve Pakola Executive Vice President, Chief Medical Officer |
Business Overview |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder. |
Financial Overview |
For the fiscal year ended 31 December 2023, Regenxbio Inc revenues decreased 20% to $90.2M. Net loss decreased 6% to $263.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Interest Expense decrease of 70% to $6.9M (expense), Research and development (including amo decrease of 4% to $211.7M (expense). |
Employees: | 344 as of Feb 22, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $504.52M as of Dec 31, 2023 |
Annual revenue (TTM): | $90.24M as of Dec 31, 2023 |
EBITDA (TTM): | -$250.81M as of Dec 31, 2023 |
Net annual income (TTM): | -$263.49M as of Dec 31, 2023 |
Free cash flow (TTM): | -$228.37M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 49,042,717 as of Apr 1, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |